Tuesday, January 10, 2017 9:24:34 AM
Molecular Med Tri-Con 2017
IMMUNOSEQUENCING AND CANCER MEDICINE
Profiling of Exhausted T Cells in Tumors Predicts PD-1 Response
Adil Daud, M.D., HS Clinical Professor, Medicine (Hematology/Oncology); Director, Melanoma Clinical Research, Helen Diller Comprehensive Cancer Center, University of California, San Francisco
Immune checkpoint blockade is revolutionizing therapy for advanced cancer. However, many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. We performed multi-parameter flow cytometry on freshly isolated metastatic melanoma samples prior to treatment and correlated subsequent clinical response with tumor immune phenotype.
http://www.triconference.com/Personalized-Diagnostics/
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM